James E Flynn Insider Trading Transactions
Get free email notifications about insider trading for James E Flynn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James E Flynn. James E Flynn is 10% Owner in CAS MEDICAL SYSTEMS INC ($CAMY.OB) and 10% Owner in AxoGen, Inc. ($LECT) and 10% Owner in PAR PHARMACEUTICAL COMPANIES, INC. ($PRX) and 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in STREAMLINE HEALTH SOLUTIONS INC. ($LANV) and 10% Owner in ANTARES PHARMA, INC. ($ATRS) and 10% Owner in VIA Pharmaceuticals, Inc. ($CAQ) and 10% Owner in DUSA PHARMACEUTICALS INC ($DUSA) and 10% Owner in HI TECH PHARMACAL CO INC ($HITK) and 10% Owner in AVADEL PHARMACEUTICALS PLC ($AVDL) and 10% Owner in INSPIRE PHARMACEUTICALS INC ($ISPH) and 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and 10% Owner in ARENA PHARMACEUTICALS INC ($ARNA) and 10% Owner in ISTA PHARMACEUTICALS INC ($ISTA) and 10% Owner in MEDICINES CO /DE ($MDCO) and 10% Owner in THIRD WAVE TECHNOLOGIES INC /WI ($TWTI) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in Cyclacel Pharmaceuticals, Inc. ($CYCC) and Director in Talon Therapeutics, Inc. ($EMLR) and 10% Owner in LUMOS PHARMA, INC. ($NLNK) and 10% Owner in NITROMED INC ($NTMD) and 10% Owner in XENOPORT INC ($XNPT) and 10% Owner in EMAGEON INC ($EMAG) and 10% Owner in CATALYST BIOSCIENCES, INC. ($CBIO) and 10% Owner in ALIMERA SCIENCES INC ($ALIM) and 10% Owner in NeuroMetrix, Inc. ($NURO) and 10% Owner in NxStage Medical, Inc. ($NXTM) and 10% Owner in aTYR PHARMA INC ($LIFE) and 10% Owner in Vanda Pharmaceuticals Inc. ($VNDA) and 10% Owner in XERIS PHARMACEUTICALS INC ($XERS) and Director in PROTEON THERAPEUTICS INC ($PRTO) and 10% Owner in eHealth, Inc. ($EHTH) and 10% Owner in ZAFGEN, INC. ($ZFGN) and 10% Owner in NeurogesX Inc ($NGSX) and 10% Owner in Invuity, Inc. ($IVTY) and 10% Owner in Dicerna Pharmaceuticals Inc ($DRNA) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and 10% Owner in TriVascular Technologies, Inc. ($TRIV) and 10% Owner in Auspex Pharmaceuticals, Inc. ($ASPX) and 10% Owner in Neos Therapeutics, Inc. ($NEOS) and 10% Owner in Schrodinger, Inc. ($SDGR) and 10% Owner in CytomX Therapeutics, Inc. ($CTMX) and Director in Acutus Medical, Inc. ($AFIB) and 10% Owner in Annexon, Inc. ($ANNX) and 10% Owner in Aclaris Therapeutics, Inc. ($ACRS) and 10% Owner in Syros Pharmaceuticals, Inc. ($SYRS) and 10% Owner in Mallinckrodt plc ($MNK) and 10% Owner in Loxo Oncology, Inc. ($LOXO) and 10% Owner in Adverum Biotechnologies, Inc. ($AAVL) and 10% Owner in REGENXBIO Inc. ($RGNX) and 10% Owner in Recro Pharma, Inc. ($REPH) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and Director in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in ShockWave Medical, Inc. ($SWAV) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and 10% Owner in Editas Medicine, Inc. ($EDIT) and Director in AveXis, Inc. ($AVXS) and 10% Owner in ARVINAS INC. ($ARVN) and 10% Owner in Homology Medicines, Inc. ($FIXX) and Director in Homology Medicines, Inc. ($FIXX) and Director in Oncorus, Inc. ($ONCR) and 10% Owner in Revolution Medicines, Inc. ($RVMD) and 10% Owner in Black Diamond Therapeutics, Inc. ($BDTX) and 10% Owner in Frequency Therapeutics, Inc. ($FREQ) and Director in DFB Healthcare Acquisitions Corp. ($DFBH) and 10% Owner in Generation Bio Co. ($GBIO) and 10% Owner in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM) and 10% Owner in Cabaletta Bio, Inc. ($CABA) and 10% Owner in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in Nkarta, Inc. ($NKTX) and 10% Owner in Edgewise Therapeutics, Inc. ($EWTX) and Director in DFP HEALTHCARE ACQUISITIONS CORP. ($DFPH) and Director in Deerfield Healthcare Technology Acquisitions Corp. ($DFHT) and 10% Owner in Terns Pharmaceuticals, Inc. ($TERN).
Latest Insider Trading Transactions of James E Flynn
Sentiment: All, ACRS, AFIB, DFBH, ADVM, ALIM, ALPN, ANNX, ATRS, ARNA, ARVN, LIFE, BOLD, ASPX, AVDL, AVXS, LECT, BDTX, CABA, CAMY.OB, CBIO, CNST, CYCC, CTMX, DFHTW, DFPHU, DRNA, DUSA, DVAX, EWTX, EDIT, EHTH, EMAG, FCSC, FREQ, GBIO, HITK, FIXX, ISPH, IVTY, ISTA, KNSA, LRMR, LOXO, NLNK, MNK, MDCO, MIRM, NEOS, NGSX, NURO, NTMD, NKTX, NXTM, ONCR, PRX, TARA, REPH, RGNX, RVMD, RYTM, RIGL, SDGR, SWAV, STDY, LANV, SYRS, EMLR, TERN, TWTI, TRIV, VNDA, CAQ, HOWL, XNPT, XERS
Page: < prev 1 2 3 4 5 6 7 ... 10 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jul 06 2016 | SYRS | Syros Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 12.50 | 280,000 | 3,500,000 | 1,466,654 | 1.2 M to 1.5 M (+23.60 %) |
Jul 06 2016 | SYRS | Syros Pharmaceutic ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 508,566 | 0 | 508,566 | 0 to 508.6 K |
Jul 06 2016 | SYRS | Syros Pharmaceutic ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 508,566 | 0 | 508,566 | 0 to 508.6 K |
Jul 06 2016 | SYRS | Syros Pharmaceutic ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 1,186,654 | 0 | 1,186,654 | 0 to 1.2 M |
Jul 06 2016 | SYRS | Syros Pharmaceutic ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 1,186,654 | 0 | 1,186,654 | 0 to 1.2 M |
Jun 22 2016 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Sell | S | 14.30 | 26,400 | 377,552 | 718,594 | 745 K to 718.6 K (-3.54 %) |
Jun 22 2016 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Sell | S | 14.20 | 178,454 | 2,533,511 | 744,994 | 923.4 K to 745 K (-19.32 %) |
Jun 16 2016 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Sell | S | 13.88 | 43,300 | 601,169 | 923,448 | 966.7 K to 923.4 K (-4.48 %) |
Jun 08 2016 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Sell | S | 13.84 | 28,080 | 388,633 | 966,748 | 994.8 K to 966.7 K (-2.82 %) |
Jun 08 2016 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Sell | S | 13.89 | 7,154 | 99,380 | 994,828 | 1 M to 994.8 K (-0.71 %) |
Jun 08 2016 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Sell | S | 14.00 | 28,502 | 399,037 | 1,001,982 | 1 M to 1 M (-2.77 %) |
Jun 02 2016 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Sell | S | 13.87 | 42,668 | 591,741 | 1,030,484 | 1.1 M to 1 M (-3.98 %) |
Jun 02 2016 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Sell | S | 13.80 | 5 | 69 | 1,073,152 | 1.1 M to 1.1 M (0.00 %) |
Jun 02 2016 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Sell | S | 13.84 | 56,835 | 786,625 | 1,073,157 | 1.1 M to 1.1 M (-5.03 %) |
May 27 2016 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Sell | S | 14.00 | 72,649 | 1,016,926 | 1,129,992 | 1.2 M to 1.1 M (-6.04 %) |
May 27 2016 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Sell | S | 14.16 | 93,965 | 1,330,808 | 1,202,641 | 1.3 M to 1.2 M (-7.25 %) |
May 27 2016 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Sell | S | 14.25 | 45,967 | 655,172 | 1,296,606 | 1.3 M to 1.3 M (-3.42 %) |
Feb 17 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.25 | 13,872 | 86,653 | 2,053,232 | 2 M to 2.1 M (+0.68 %) |
Feb 17 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.25 | 28,377 | 177,260 | 561,328 | 533 K to 561.3 K (+5.32 %) |
Feb 17 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.25 | 22,296 | 139,274 | 441,043 | 418.7 K to 441 K (+5.32 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.19 | 504 | 3,119 | 2,039,360 | 2 M to 2 M (+0.02 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.19 | 1,030 | 6,374 | 532,951 | 531.9 K to 533 K (+0.19 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.19 | 810 | 5,013 | 418,747 | 417.9 K to 418.7 K (+0.19 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.23 | 32,501 | 202,556 | 2,038,856 | 2 M to 2 M (+1.62 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.23 | 66,486 | 414,361 | 531,921 | 465.4 K to 531.9 K (+14.28 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.23 | 52,239 | 325,569 | 417,937 | 365.7 K to 417.9 K (+14.28 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 5.73 | 24,484 | 140,271 | 2,006,355 | 2 M to 2 M (+1.24 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 5.73 | 50,086 | 286,948 | 465,435 | 415.3 K to 465.4 K (+12.06 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 5.73 | 39,353 | 225,457 | 365,698 | 326.3 K to 365.7 K (+12.06 %) |
Feb 23 2016 | XNPT | XENOPORT INC | Flynn James E | 10% Owner | Buy | P | 3.99 | 11,745 | 46,843 | 2,746,650 | 2.7 M to 2.7 M (+0.43 %) |
Feb 23 2016 | XNPT | XENOPORT INC | Flynn James E | 10% Owner | Buy | P | 3.99 | 9,228 | 36,804 | 2,158,084 | 2.1 M to 2.2 M (+0.43 %) |
Feb 16 2016 | XNPT | XENOPORT INC | Flynn James E | 10% Owner | Buy | P | 3.92 | 19,725 | 77,381 | 2,734,905 | 2.7 M to 2.7 M (+0.73 %) |
Feb 16 2016 | XNPT | XENOPORT INC | Flynn James E | 10% Owner | Buy | P | 3.92 | 15,499 | 60,803 | 2,148,856 | 2.1 M to 2.1 M (+0.73 %) |
Feb 16 2016 | XNPT | XENOPORT INC | Flynn James E | 10% Owner | Buy | P | 3.76 | 1,157,189 | 4,349,642 | 2,715,180 | 1.6 M to 2.7 M (+74.27 %) |
Feb 16 2016 | XNPT | XENOPORT INC | Flynn James E | 10% Owner | Buy | P | 3.76 | 909,221 | 3,417,580 | 2,133,357 | 1.2 M to 2.1 M (+74.27 %) |
Feb 16 2016 | XNPT | XENOPORT INC | Flynn James E | 10% Owner | Buy | P | 3.96 | 1,557,991 | 6,166,840 | 1,557,991 | 0 to 1.6 M |
Feb 16 2016 | XNPT | XENOPORT INC | Flynn James E | 10% Owner | Buy | P | 3.96 | 1,224,136 | 4,845,375 | 1,224,136 | 0 to 1.2 M |
Feb 08 2016 | EDIT | Editas Medicine, I ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 854,700 | 0 | 0 | |
Feb 08 2016 | EDIT | Editas Medicine, I ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 854,700 | 0 | 0 | |
Feb 08 2016 | EDIT | Editas Medicine, I ... | Flynn James E | 10% Owner | Buy | P | 16.00 | 100,000 | 1,600,000 | 954,700 | 854.7 K to 954.7 K (+11.70 %) |
Feb 08 2016 | EDIT | Editas Medicine, I ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 854,700 | 0 | 854,700 | 0 to 854.7 K |
Feb 08 2016 | EDIT | Editas Medicine, I ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 854,700 | 0 | 854,700 | 0 to 854.7 K |
Feb 19 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 117,998 | 0 | 0 | |
Feb 19 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 117,996 | 0 | 0 | |
Feb 19 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 1,182,941 | 0 | 0 | |
Feb 19 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 67,448 | 0 | 0 | |
Feb 19 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Option Exercise | P | 0.00 | 117,998 | 0 | 0 | |
Feb 19 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Option Exercise | P | 0.00 | 117,996 | 0 | 0 | |
Feb 19 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Buy | P | 20.00 | 112,000 | 2,240,000 | 112,000 | 0 to 112 K |
Feb 19 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Buy | P | 20.00 | 88,000 | 1,760,000 | 88,000 | 0 to 88 K |
Feb 19 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Buy | P | 20.00 | 163,702 | 3,274,040 | 413,611 | 249.9 K to 413.6 K (+65.50 %) |
Feb 19 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Buy | P | 20.00 | 122,793 | 2,455,860 | 1,623,089 | 1.5 M to 1.6 M (+8.18 %) |
Feb 19 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Buy | C | 0.00 | 117,998 | 0 | 249,909 | 131.9 K to 249.9 K (+89.45 %) |
Feb 19 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Buy | C | 0.00 | 117,996 | 0 | 1,500,296 | 1.4 M to 1.5 M (+8.54 %) |
Feb 19 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Buy | C | 0.00 | 1,182,941 | 0 | 1,382,300 | 199.4 K to 1.4 M (+593.37 %) |
Feb 19 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Buy | C | 0.00 | 67,448 | 0 | 199,359 | 131.9 K to 199.4 K (+51.13 %) |
Feb 19 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Buy | P | 18.48 | 131,911 | 2,437,715 | 131,911 | 0 to 131.9 K |
Feb 19 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Buy | P | 18.48 | 131,911 | 2,437,715 | 131,911 | 0 to 131.9 K |
Feb 12 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Option Exercise | A | 20.00 | 8,385 | 167,700 | 8,385 | |
Feb 12 2016 | AVXS | AveXis, Inc. | Flynn James E | Director | Option Exercise | A | 20.00 | 18,111 | 362,220 | 18,111 | |
Jan 22 2016 | XNPT | XENOPORT INC | Flynn James E | 10% Owner | Buy | P | 4.09 | 346,417 | 1,418,404 | 6,667,391 | 6.3 M to 6.7 M (+5.48 %) |
Dec 18 2015 | VNDA | Vanda Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 8.97 | 3,239 | 29,042 | 1,103,617 | 1.1 M to 1.1 M (+0.29 %) |
Dec 18 2015 | VNDA | Vanda Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 8.97 | 4,441 | 39,820 | 2,740,122 | 2.7 M to 2.7 M (+0.16 %) |
Dec 18 2015 | VNDA | Vanda Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 8.97 | 3,490 | 31,293 | 2,152,952 | 2.1 M to 2.2 M (+0.16 %) |
Dec 17 2015 | LANV | STREAMLINE HEALTH ... | Flynn James E | 10% Owner | Sell | S | 1.20 | 226,000 | 271,968 | 1,875,500 | 2.1 M to 1.9 M (-10.75 %) |
Dec 17 2015 | LANV | STREAMLINE HEALTH ... | Flynn James E | 10% Owner | Sell | S | 1.23 | 116,464 | 142,831 | 2,101,500 | 2.2 M to 2.1 M (-5.25 %) |
Dec 17 2015 | LANV | STREAMLINE HEALTH ... | Flynn James E | 10% Owner | Sell | S | 1.34 | 54,795 | 73,486 | 2,217,964 | 2.3 M to 2.2 M (-2.41 %) |
Dec 11 2015 | VNDA | Vanda Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 8.61 | 93,634 | 806,086 | 1,100,378 | 1 M to 1.1 M (+9.30 %) |
Dec 11 2015 | VNDA | Vanda Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 8.61 | 128,374 | 1,105,159 | 2,726,895 | 2.6 M to 2.7 M (+4.94 %) |
Dec 11 2015 | VNDA | Vanda Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 8.61 | 100,864 | 868,328 | 2,158,248 | 2.1 M to 2.2 M (+4.90 %) |
Dec 11 2015 | VNDA | Vanda Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 8.59 | 29,902 | 256,864 | 1,006,744 | 976.8 K to 1 M (+3.06 %) |
Dec 11 2015 | VNDA | Vanda Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 8.59 | 32,211 | 276,699 | 2,598,521 | 2.6 M to 2.6 M (+1.26 %) |
Dec 11 2015 | VNDA | Vanda Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 8.59 | 40,997 | 352,172 | 2,057,384 | 2 M to 2.1 M (+2.03 %) |
Dec 11 2015 | VNDA | Vanda Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 9.00 | 11,506 | 103,554 | 976,842 | 965.3 K to 976.8 K (+1.19 %) |
Dec 11 2015 | VNDA | Vanda Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 9.00 | 15,775 | 141,975 | 2,566,310 | 2.6 M to 2.6 M (+0.62 %) |
Dec 11 2015 | VNDA | Vanda Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 9.00 | 12,395 | 111,555 | 2,016,387 | 2 M to 2 M (+0.62 %) |
Dec 11 2015 | VNDA | Vanda Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 8.21 | 213,358 | 1,751,883 | 965,336 | 752 K to 965.3 K (+28.37 %) |
Dec 11 2015 | VNDA | Vanda Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 8.21 | 292,515 | 2,401,841 | 2,550,535 | 2.3 M to 2.6 M (+12.95 %) |
Dec 11 2015 | VNDA | Vanda Pharmaceutic ... | Flynn James E | 10% Owner | Buy | P | 8.21 | 229,833 | 1,887,159 | 2,003,992 | 1.8 M to 2 M (+12.95 %) |
Dec 08 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.04 | 27,530 | 83,774 | 728,718 | 701.2 K to 728.7 K (+3.93 %) |
Dec 08 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.04 | 27,529 | 83,771 | 4,760,408 | 4.7 M to 4.8 M (+0.58 %) |
Dec 08 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 68,294 | 204,848 | 701,188 | 632.9 K to 701.2 K (+10.79 %) |
Dec 08 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 68,294 | 204,848 | 4,732,879 | 4.7 M to 4.7 M (+1.46 %) |
Dec 08 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.01 | 40,301 | 121,169 | 632,894 | 592.6 K to 632.9 K (+6.80 %) |
Dec 08 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.01 | 40,301 | 121,169 | 4,664,585 | 4.6 M to 4.7 M (+0.87 %) |
Dec 03 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 53,487 | 160,589 | 592,593 | 539.1 K to 592.6 K (+9.92 %) |
Dec 03 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 53,486 | 160,586 | 4,624,284 | 4.6 M to 4.6 M (+1.17 %) |
Dec 03 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.98 | 55,257 | 164,876 | 539,106 | 483.8 K to 539.1 K (+11.42 %) |
Dec 03 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.98 | 55,257 | 164,876 | 4,570,798 | 4.5 M to 4.6 M (+1.22 %) |
Dec 03 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.05 | 12,882 | 39,273 | 483,849 | 471 K to 483.8 K (+2.74 %) |
Dec 03 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.05 | 12,883 | 39,276 | 4,515,541 | 4.5 M to 4.5 M (+0.29 %) |
Nov 10 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.98 | 36,625 | 109,241 | 470,967 | 434.3 K to 471 K (+8.43 %) |
Nov 10 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.98 | 36,625 | 109,241 | 4,502,658 | 4.5 M to 4.5 M (+0.82 %) |
Nov 03 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 8,271 | 24,813 | 434,342 | 426.1 K to 434.3 K (+1.94 %) |
Nov 03 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 8,271 | 24,813 | 4,466,033 | 4.5 M to 4.5 M (+0.19 %) |
Oct 29 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.99 | 13,165 | 39,363 | 426,071 | 412.9 K to 426.1 K (+3.19 %) |
Oct 29 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.99 | 13,165 | 39,363 | 4,457,762 | 4.4 M to 4.5 M (+0.30 %) |
Oct 29 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 16,506 | 49,518 | 412,906 | 396.4 K to 412.9 K (+4.16 %) |
Oct 29 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 16,506 | 49,518 | 4,444,597 | 4.4 M to 4.4 M (+0.37 %) |
Oct 26 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 17,117 | 51,361 | 396,400 | 379.3 K to 396.4 K (+4.51 %) |
Oct 26 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 17,116 | 51,358 | 4,428,091 | 4.4 M to 4.4 M (+0.39 %) |
Oct 26 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 12,090 | 36,270 | 379,283 | 367.2 K to 379.3 K (+3.29 %) |
Oct 26 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 12,091 | 36,273 | 4,410,975 | 4.4 M to 4.4 M (+0.27 %) |
Oct 26 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 975 | 2,925 | 367,193 | 366.2 K to 367.2 K (+0.27 %) |
Oct 26 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 975 | 2,925 | 4,398,884 | 4.4 M to 4.4 M (+0.02 %) |
Oct 21 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 80,342 | 241,042 | 366,218 | 285.9 K to 366.2 K (+28.10 %) |
Oct 21 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 80,342 | 241,042 | 4,397,909 | 4.3 M to 4.4 M (+1.86 %) |
Oct 21 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 50,065 | 150,060 | 285,876 | 235.8 K to 285.9 K (+21.23 %) |
Oct 21 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 50,065 | 150,060 | 4,317,567 | 4.3 M to 4.3 M (+1.17 %) |
Oct 21 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.92 | 64,613 | 188,825 | 235,811 | 171.2 K to 235.8 K (+37.74 %) |
Oct 21 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.92 | 64,613 | 188,825 | 4,267,502 | 4.2 M to 4.3 M (+1.54 %) |
Oct 14 2015 | CTMX | CytomX Therapeutic ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 160,512 | 0 | 0 | |
Oct 14 2015 | CTMX | CytomX Therapeutic ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 160,512 | 0 | 0 | |
Oct 14 2015 | CTMX | CytomX Therapeutic ... | Flynn James E | 10% Owner | Buy | P | 12.00 | 114,488 | 1,373,856 | 275,000 | 160.5 K to 275 K (+71.33 %) |
Oct 14 2015 | CTMX | CytomX Therapeutic ... | Flynn James E | 10% Owner | Buy | P | 12.00 | 510,512 | 6,126,144 | 671,024 | 160.5 K to 671 K (+318.05 %) |
Oct 14 2015 | CTMX | CytomX Therapeutic ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 160,512 | 0 | 160,512 | 0 to 160.5 K |
Oct 14 2015 | CTMX | CytomX Therapeutic ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 160,512 | 0 | 160,512 | 0 to 160.5 K |
Oct 09 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.53 | 71,540 | 180,710 | 171,198 | 99.7 K to 171.2 K (+71.79 %) |
Oct 09 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.53 | 71,540 | 180,710 | 4,202,889 | 4.1 M to 4.2 M (+1.73 %) |
Oct 09 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.50 | 19,817 | 49,543 | 99,658 | 79.8 K to 99.7 K (+24.82 %) |
Oct 09 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.50 | 19,816 | 49,540 | 4,131,349 | 4.1 M to 4.1 M (+0.48 %) |
Oct 09 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.30 | 69,536 | 159,724 | 79,841 | 10.3 K to 79.8 K (+674.78 %) |
Oct 09 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.30 | 69,536 | 159,724 | 4,111,533 | 4 M to 4.1 M (+1.72 %) |
Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.69 | 83,930 | 142,018 | 5,348,776 | 5.4 M to 5.3 M (-1.54 %) |
Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.69 | 106,820 | 180,750 | 6,807,533 | 6.9 M to 6.8 M (-1.54 %) |
Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.69 | 59,248 | 100,254 | 3,294,817 | 3.4 M to 3.3 M (-1.77 %) |
Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.83 | 34,450 | 63,044 | 5,432,706 | 5.5 M to 5.4 M (-0.63 %) |
Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.83 | 43,845 | 80,236 | 6,914,353 | 7 M to 6.9 M (-0.63 %) |
Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.82 | 11,081 | 20,176 | 3,354,065 | 3.4 M to 3.4 M (-0.33 %) |
Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.82 | 15,696 | 28,579 | 5,467,156 | 5.5 M to 5.5 M (-0.29 %) |
Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.82 | 19,976 | 36,372 | 6,958,198 | 7 M to 7 M (-0.29 %) |
Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.81 | 23,700 | 42,897 | 3,365,146 | 3.4 M to 3.4 M (-0.70 %) |
Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.81 | 33,572 | 60,765 | 5,482,852 | 5.5 M to 5.5 M (-0.61 %) |
Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.81 | 42,728 | 77,338 | 6,978,174 | 7 M to 7 M (-0.61 %) |
Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.81 | 368,676 | 669,036 | 5,516,424 | 5.9 M to 5.5 M (-6.26 %) |
Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.81 | 469,224 | 851,501 | 7,020,902 | 7.5 M to 7 M (-6.26 %) |
Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.80 | 226,857 | 408,774 | 5,885,100 | 6.1 M to 5.9 M (-3.71 %) |
Sep 30 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 1.80 | 288,726 | 520,255 | 7,490,126 | 7.8 M to 7.5 M (-3.71 %) |
Sep 22 2015 | LECT | AxoGen, Inc. | Flynn James E | 10% Owner | Sell | S | 5.50 | 345,000 | 1,897,983 | 3,381,439 | 3.7 M to 3.4 M (-9.26 %) |
Sep 22 2015 | RGNX | REGENXBIO Inc. | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 397,079 | 0 | 0 | |
Sep 22 2015 | RGNX | REGENXBIO Inc. | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 771,963 | 0 | 0 | |
Sep 22 2015 | RGNX | REGENXBIO Inc. | Flynn James E | 10% Owner | Buy | P | 22.00 | 49,000 | 1,078,000 | 49,000 | 0 to 49 K |
Sep 22 2015 | RGNX | REGENXBIO Inc. | Flynn James E | 10% Owner | Buy | P | 22.00 | 38,500 | 847,000 | 38,500 | 0 to 38.5 K |
Sep 22 2015 | RGNX | REGENXBIO Inc. | Flynn James E | 10% Owner | Buy | P | 22.00 | 87,500 | 1,925,000 | 1,256,542 | 1.2 M to 1.3 M (+7.48 %) |
Sep 22 2015 | RGNX | REGENXBIO Inc. | Flynn James E | 10% Owner | Buy | C | 0.00 | 397,079 | 0 | 1,169,042 | 772 K to 1.2 M (+51.44 %) |
Sep 22 2015 | RGNX | REGENXBIO Inc. | Flynn James E | 10% Owner | Buy | C | 0.00 | 771,963 | 0 | 771,963 | 0 to 772 K |
Jul 28 2015 | NEOS | Neos Therapeutics, ... | Flynn James E | 10% Owner | Option Exercise | X | 0.00 | 104,166 | 0 | 0 | |
Jul 28 2015 | NEOS | Neos Therapeutics, ... | Flynn James E | 10% Owner | Option Exercise | X | 0.00 | 104,166 | 0 | 0 | |
Jul 28 2015 | NEOS | Neos Therapeutics, ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 500,000 | 0 | 0 | |
Jul 28 2015 | NEOS | Neos Therapeutics, ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 500,000 | 0 | 0 |